South Australian Meningococcal B Vaccine Herd Immunity Study
Phase of Trial: Phase IV
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
- 22 Jan 2018 Planned number of patients changed from 45000 to 24300.
- 22 Jan 2018 Planned End Date changed from 31 Jul 2020 to 30 Jun 2020.
- 17 Mar 2017 Status changed to recruiting.